502u83 has been researched along with Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Clendeninn, NJ; Hohneker, JA; Janisch, L; Lucas, VS; Ratain, MJ; Ravitch, J; Schilsky, RL; Tuttle, RL; Vogelzang, NJ | 1 |
| Alberts, DS; Brodar, F; Lam, KS; Matias, B; Modiano, M; Peng, YM; Sol Lucas, V; Tuttle, R; Wargin, W | 1 |
| Bair, KW; Brown, TD; Havlin, KA; Kuhn, JG; Langevin, AM; Lucas, VS; Purvis, J; Turner, JN; Von Hoff, DD; Weiss, GR | 1 |
1 trial(s) available for 502u83 and Neoplasms
| Article | Year |
|---|---|
Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion.
Topics: Adult; Aged; Anthracenes; Antineoplastic Agents; Chromatography, High Pressure Liquid; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Electrocardiography; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Respiratory Insufficiency | 1993 |
2 other study(ies) available for 502u83 and Neoplasms
| Article | Year |
|---|---|
Phase I and pharmacokinetic study of 502U83 (an arylmethylaminopropanediol) in cancer patients.
Topics: Anthracenes; Antineoplastic Agents; Chromatography, High Pressure Liquid; Drug Evaluation; Female; Half-Life; Humans; Intercalating Agents; Male; Neoplasms | 1992 |
Phase I and clinical pharmacology trial of 502U83 using a monthly single dose schedule.
Topics: Adult; Aged; Anthracenes; Antineoplastic Agents; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Electrocardiography; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms | 1990 |